New pre-pandemic influenza vaccines: An egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 6, 2007, Pages 665-671

  Hoelscher, M A ^a   Jayashankar, L ^b   Garg, S ^a   Veguilla, V ^a   Lu, X ^a   Singh, N ^b   Katz, J M ^a   Mittal, S K ^b   Sambhara, S ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADJUVANT; INFLUENZA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DISEASE OUTBREAKS; DRUG DESIGN; EGGS; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; TIME FACTORS;

EID: 36148977602     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100418     Document Type: Article

References (58)

1. de Jong, J.C., Claas, E.C.J., Osterhaus, A.D.M.E., Webster, R.G. & Lim, W.L. A pandemic warning? Nature 389, 554 (1997).
2. Subbarao, K. et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279, 393-396 (1998).
3. OIE. Update on avian influenza in animals (type H5) 〈http://www.oie. int/downld/AVIAN%20INFLUENZA/A_AI-Asia.htm〉 (2007).
4. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO 〈http://www.who.int/csr/disease/ avian_influenza/country/cases_table_2007_07_11/en/index.html〉 (2007). Accessed 11 July 2007.
5. Chen, H. et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc. Natl. Acad. Sci. USA 103, 2845-2850 (2006).
6. World Health Organization. Avian influenze ("bird flu")-Fact sheet 〈http://www.who.int/mediacentre/factsheets/avian_influenza/en/ #role〉 (2007). Accessed 12 October 2007.
7. Kandun, I.N. et al. Three Indonesian clusters of H5N1 virus infection in 2005. N. Engl. J. Med. 355, 2186-2194 (2006).
8. Ungchusak, K. et al. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 352, 333-340 (2005).
9. The World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis. 11, 1515-1521 (2005).
10. Li, K.S. et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430, 209-213 (2004).
11. Horimoto, T. & Kawaoka, Y. Strategies for developing vaccines against H5N1 influenza A viruses. Trends Mol. Med. 12, 506-514 (2006).
12. Treanor, J.J. et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19, 1732-1737 (2001).
13. Fodor, E., Devenish, L., Engelhardt, O.G., Palese, P., Brownlee, G.G. & Garcia-Sastre, A. Rescue of influenza A virus from recombinant DNA. J. Virol. 73, 9679-9682 (1999).
14. Hoffmann, E., Krauss, S., Perez, D., Webby, R. & Webster, R.G. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20, 3165-3170 (2002).
15. Horimoto, T. & Kawaoka, Y. Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. J. Virol. 68, 3120-3128 (1994).
16. Luytjes, W., Krystal, M., Enami, M., Parvin, J.D. & Palese, P. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 59, 1107-1113 (1989).
17. US Food and Drug Administration. First "bird flu" vaccine for humans approved 〈http://www.fda.gov/consumer/updates/birdflu043007. html〉 (2007). Accessed 12 October 2007.
18. Maassab, H.F. & DeBorde, D.C. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 3, 355-369 (1985).
19. World Health Organization. Global pandemic influenza action plan to increase vaccine supply 〈http://www.who.int/csr/resources/publications/ influenza/CDS_EPR_GIP_2006_1.pdf〉 (2006). Accessed 10 July 2007.
20. Leroux-Roels, I. et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370, 580-589 (2007).
21. Sambhara, S. & Poland, G.A. Avian influenza vaccines: what's all the flap? Lancet 367, 1636-1638 (2006).
22. Cinatl, J.J., Michaelis, M. & Doerr, H.W. The threat of avian influenza A (H5N1). Part IV: development of vaccines. Med. Microbiol. Immunol. 196, 213-225 (2007).
23. Gillim-Ross, L. & Subbarao, K. Emerging respiratory viruses: challenges and vaccine strategies. Clin. Microbiol. Rev. 19, 614-636 (2006).
24. Poland, G.A., Jacobson, R.M. & Targonski, P.V. Avian and pandemic influenza: an overview. Vaccine 25, 3057-3061 (2007).
25. Simmons, C.P. et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 4, e178 (2007).
26. Subbarao, K. & Luke, C. H5N1 viruses and vaccines. PLoS Pathog. 3, e40 (2007).
27. Hoelscher, M.A. et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367, 475-481 (2006).
28. Gao, W. et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 80, 1959-1964 (2006).
29. Bonnet, M.C. et al. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol. Lett. 74, 11-25 (2000).
30. Eisenberger, A., Elliott, B.M. & Kaufman, H.L. Viral vaccines for cancer immunotherapy. Hematol. Oncol. Clin. North Am. 20, 661-687 (2006).
31. Fooks, A.R. et al. High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model. Virology 210, 456-465 (1995).
32. Gao, W. et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362, 1895-1896 (2003).
33. Gomez-Roman, V.R. HIV/AIDS prevention programs in developing countries are deficient without an appropriate scientific research infrastructure. AIDS 17, 1114-1116 (2003).
34. Hashimoto, M., Boyer, J.L., Hackett, N.R., Wilson, J.M. & Crystal, R.G. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect. Immun. 73, 6885-6891 (2005).
35. Lubeck, M.D. et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc. Natl. Acad. Sci. USA 86, 6763-6767 (1989).
36. Morse, M.A. Virus-based therapies for colon cancer. Expert Opin. Biol. Ther. 5, 1627-1633 (2005).
37. Ponnazhagan, S. et al. Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant. Hum. Gene Ther. 15, 856-864 (2004).
38. Prevec, L., Christie, B.S., Laurie, K.E., Bailey, M.M., Graham, F.L. & Rosenthal, K.L. Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. J. Acquir. Immune Defic. Syndr. 4, 568-576 (1991).
39. Sullivan, N.J. et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424, 681-684 (2003).
40. Catanzaro, A.T. et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194, 1638-1649 (2006).
41. Lin, X. et al. A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol. Ther. 6, 648-653 (2007).
42. Van Kampen, K.R. Recombinant vaccine technology in veterinary medicine. Vet. Clin. North Am. Small Anim. Pract. 31, 535-538, vii (2001).
43. Zhu, J., Huang, X. & Yang, Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J. Virol. 81, 3170-3180 (2007).
44. Treanor, J.J., Campbell, J.D., Zangwill, K.M., Rowe, T. & Wolff, M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354, 1343-1351 (2006).
45. Bresson, J.L. et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367, 1657-1664 (2006).
46. Lin, J. et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368, 991-997 (2006).
47. Nicholson, K.G. et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357, 1937-1943 (2001).
48. Condon, C. A vaccine in 50 days? Lancet 366, 1686 (2005).
49. Sambhara, S. et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell. Immunol. 211, 143-153 (2001).
50. Stephenson, I. et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191, 1210-1215 (2005).
51. Capone, S. et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J. Immunol. 177, 7462-7471 (2006).
52. Rosenthal, K.L. & Gallichan, W.S. Challenges for vaccination against sexually-transmitted diseases: induction and long-term maintenance of mucosal immune responses in the female genital tract. Semin. Immunol. 9, 303-314 (1997).
53. Flanagan, B., Pringle, C.R. & Leppard, K.N. A recombinant human adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long-lived immune responses in mice. J. Gen. Virol. 78 (Part 5), 991-997 (1997).
54. Schwartz, J.A. et al. Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology 366, 166-173 (2007).
55. Sambhara, S. et al. Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes. J. Infect. Dis. 177, 1266-1274 (1998).
56. Goncalves, M.A. & de Vries, A.A. Adenovirus: from foe to friend. Rev. Med. Virol. 16, 167-186 (2006).
57. Rowe, T. et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 37, 937-943 (1999).
58. Stephenson, I., Wood, J.M., Nicholson, K.G., Charlett, A. & Zambon, M.C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 103, 91-95 (2004).